Edgar J. Schoen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Edgar J. Schoen has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Trinh T. To
Department of Genetics, Kaiser Permanente Medical Center and Division of Research, Kaiser Permanente Medical Care Program, Oakland, California
4 shared publicationsCarole Limata
3 shared publicationsChristopher J. Colby
Department of Genetics, Kaiser Permanente Medical Center and Division of Research, Kaiser Permanente Medical Care Program, Oakland, California
2 shared publicationsBruce H. Fireman
Division of Research, Kaiser Permanente Northern California Region, Oakland, California
1 shared publicationCarol Norem
Regional Perinatal Screening Program and Departments of Genetics and Perinatology, Kaiser Permanente Medical Center, Oakland, California
1 shared publicationChristopher J Colby
Departments of Genetics and Pediatrics and Division of Research, Kaiser Permanente Medical Care Program, Oakland
1 shared publication
Latest Publications
- 1 July 2006
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 118 (1) , 385-387
Ignoring Evidence of Circumcision Benefits
- 1 July 2006
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 118 (1) , 385-387
Ignoring Evidence of Circumcision Benefits
- 1 March 2006
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 175 (3) , 1111-1115
Cost Analysis of Neonatal Circumcision in a Large Health Maintenance Organization
We studied the costs of newborn circumcision in relation to its health benefits later in life. We conducted a retrospective database analysis using direct internal cost data from Kaiser Permanente Northern California-a large health maintenance organization-and published cost data (including the cost of medically indicated postneonatal circumcision). The study cohort consisted of 14,893 male infants born in 1996. One-way sensitivity analysis was used to demonstrate the impact of selected variables in the model. Monte Carlo analysis was used to determine the 95% confidence intervals. Postneonatal circumcision was 10 times as expensive as neonatal circumcision (1,921 dollars per infant vs 165 dollars per newborn), and was medically indicated for 9.6% of uncircumcised males. Cost benefits of circumcision resulted from prevention of infant urinary tract infection, balanoposthitis, phimosis, HIV infection and penile cancer. Assuming initial neonatal circumcision cost to be 200 dollars, the future health care cost offset (avoided) was calculated as 183 dollars (range 93 dollars to 303 dollars in 95% of simulations). Multiple lifetime medical benefits of neonatal circumcision can be achieved at little or no cost. Because postneonatal circumcision is so expensive, its rate is the most important factor determining future cost savings from newborn circumcision.
- 1 March 2006
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 175 (3) , 1111-1115
Cost Analysis of Neonatal Circumcision in a Large Health Maintenance Organization
We studied the costs of newborn circumcision in relation to its health benefits later in life. We conducted a retrospective database analysis using direct internal cost data from Kaiser Permanente Northern California-a large health maintenance organization-and published cost data (including the cost of medically indicated postneonatal circumcision). The study cohort consisted of 14,893 male infants born in 1996. One-way sensitivity analysis was used to demonstrate the impact of selected variables in the model. Monte Carlo analysis was used to determine the 95% confidence intervals. Postneonatal circumcision was 10 times as expensive as neonatal circumcision (1,921 dollars per infant vs 165 dollars per newborn), and was medically indicated for 9.6% of uncircumcised males. Cost benefits of circumcision resulted from prevention of infant urinary tract infection, balanoposthitis, phimosis, HIV infection and penile cancer. Assuming initial neonatal circumcision cost to be 200 dollars, the future health care cost offset (avoided) was calculated as 183 dollars (range 93 dollars to 303 dollars in 95% of simulations). Multiple lifetime medical benefits of neonatal circumcision can be achieved at little or no cost. Because postneonatal circumcision is so expensive, its rate is the most important factor determining future cost savings from newborn circumcision.
- 1 August 2005
- Published by BMJ in Archives of Disease in Childhood
- Vol. 90 (8) , 772-773
Circumcision for preventing urinary tract infections in boys: North American view
- 1 August 2005
- Published by BMJ in Archives of Disease in Childhood
- Vol. 90 (8) , 772-773
Circumcision for preventing urinary tract infections in boys: North American view
- 1 December 2004
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 114 (6) , e683-e688
The Key Role of Newborn Thyroid Scintigraphy With Isotopic Iodide (123I) in Defining and Managing Congenital Hypothyroidism
Background. Thyroid imaging with isotopic iodide (123I) or technetium Tc 99m pertechnetate has been available for decades but is not routinely used in newborn infants diagnosed with congenital hypothyroidism (CH). Among clinicians who believe that presence, absence, or abnormal location of a thyroid does not alter management of CH, imaging is not advocated for anatomic diagnosis of CH.
- 1 December 2004
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 114 (6) , e683-e688
The Key Role of Newborn Thyroid Scintigraphy With Isotopic Iodide (123I) in Defining and Managing Congenital Hypothyroidism
Background. Thyroid imaging with isotopic iodide (123I) or technetium Tc 99m pertechnetate has been available for decades but is not routinely used in newborn infants diagnosed with congenital hypothyroidism (CH). Among clinicians who believe that presence, absence, or abnormal location of a thyroid does not alter management of CH, imaging is not advocated for anatomic diagnosis of CH.
- 1 July 2003
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 102 (1) , 167-172
Maternal serum unconjugated estriol as a predictor for Smith–Lemli–Opitz syndrome and other fetal conditions
To assess the clinical value of low maternal serum unconjugated estriol (E3) level for diagnosing Smith-Lemli-Opitz syndrome and other fetal clinical conditions in pregnant members of a large health maintenance organization. We studied serum unconjugated E3 levels in 120,071 gravidas having California Expanded Alpha-Fetoprotein prenatal screening at 15-20 weeks' gestation during a 5-year period. Of the 120,071 women, 323 (0.27%) had low unconjugated E3 levels (less than or equal to 0.2 ng/mL, or 0.15 multiples of the median). Excluding women who were screened too early or who had indeterminate screening results, 103 (0.08%) women with unexplained low unconjugated E3 level remained; of these 103 women, 33 had negative screening results and 68 had positive screening results, and two were tested too late for interpretation. Intrauterine fetal death occurred in 39 (57%) of the 68 women with low unconjugated E3 and positive screening results and occurred in two (6%) of the 33 women with low unconjugated E3 levels and negative screening results, a significant difference (P <.001). Two cases of Smith-Lemli-Opitz syndrome were identified and the patients did not survive the neonatal period; one was a therapeutic abortion for severe oligohydramnios, and the other died at age 48 hours. Low unconjugated E3 level also predicted presence of steroid sulfatase deficiency, a much more common X-linked skin disorder characterized by ichthyosis. Low maternal serum unconjugated E3 diagnosed more cases of steroid sulfatase deficiency and undetected intrauterine fetal death than Smith-Lemli-Opitz syndrome (1:60,000 prevalence), although the clinical importance of having this information prenatally is uncertain.
- 1 July 2003
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 102 (1) , 167-172
Maternal serum unconjugated estriol as a predictor for Smith–Lemli–Opitz syndrome and other fetal conditions
To assess the clinical value of low maternal serum unconjugated estriol (E3) level for diagnosing Smith-Lemli-Opitz syndrome and other fetal clinical conditions in pregnant members of a large health maintenance organization. We studied serum unconjugated E3 levels in 120,071 gravidas having California Expanded Alpha-Fetoprotein prenatal screening at 15-20 weeks' gestation during a 5-year period. Of the 120,071 women, 323 (0.27%) had low unconjugated E3 levels (less than or equal to 0.2 ng/mL, or 0.15 multiples of the median). Excluding women who were screened too early or who had indeterminate screening results, 103 (0.08%) women with unexplained low unconjugated E3 level remained; of these 103 women, 33 had negative screening results and 68 had positive screening results, and two were tested too late for interpretation. Intrauterine fetal death occurred in 39 (57%) of the 68 women with low unconjugated E3 and positive screening results and occurred in two (6%) of the 33 women with low unconjugated E3 levels and negative screening results, a significant difference (P <.001). Two cases of Smith-Lemli-Opitz syndrome were identified and the patients did not survive the neonatal period; one was a therapeutic abortion for severe oligohydramnios, and the other died at age 48 hours. Low unconjugated E3 level also predicted presence of steroid sulfatase deficiency, a much more common X-linked skin disorder characterized by ichthyosis. Low maternal serum unconjugated E3 diagnosed more cases of steroid sulfatase deficiency and undetected intrauterine fetal death than Smith-Lemli-Opitz syndrome (1:60,000 prevalence), although the clinical importance of having this information prenatally is uncertain.
- 1 July 2003
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 102 (1) , 167-172
Maternal Serum Unconjugated Estriol as a Predictor for Smith–Lemli–Opitz Syndrome and Other Fetal Conditions
OBJECTIVE To assess the clinical value of low maternal serum unconjugated estriol (E3) level for diagnosing Smith–Lemli–Opitz syndrome and other fetal clinical conditions in pregnant members of a large health maintenance organization. METHODS We studied serum unconjugated E3 levels in 120,071 gravidas having California Expanded Alpha-Feto-protein prenatal screening at 15–20 weeks' gestation during a 5-year period. RESULTS Of the 120,071 women, 323 (0.27%) had low unconjugated E3 levels (less than or equal to 0.2 ng/mL, or 0.15 multiples of the median). Excluding women who were screened too early or who had indeterminate screening results, 103 (0.08%) women with unexplained low unconjugated E3 level remained; of these 103 women, 33 had negative screening results and 68 had positive screening results, and two were tested too late for interpretation. Intrauterine fetal death occurred in 39 (57%) of the 68 women with low unconjugated E3 and positive screening results and occurred in two (6%) of the 33 women with low unconjugated E3 levels and negative screening results, a significant difference (P < .001). Two cases of Smith–Lemli–Opitz syndrome were identified and the patients did not survive the neonatal period; one was a therapeutic abortion for severe oligohydramnios, and the other died at age 48 hours. Low unconjugated E3 level also predicted presence of steroid sulfatase deficiency, a much more common X-linked skin disorder characterized by ichthyosis. CONCLUSION Low maternal serum unconjugated E3 diagnosed more cases of steroid sulfatase deficiency and undetected intrauterine fetal death than Smith–Lemli–Opitz syndrome (1:60,000 prevalence), although the clinical importance of having this information prenatally is uncertain.
- 1 July 2003
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 102 (1) , 167-172
Maternal Serum Unconjugated Estriol as a Predictor for Smith–Lemli–Opitz Syndrome and Other Fetal Conditions
OBJECTIVE To assess the clinical value of low maternal serum unconjugated estriol (E3) level for diagnosing Smith–Lemli–Opitz syndrome and other fetal clinical conditions in pregnant members of a large health maintenance organization. METHODS We studied serum unconjugated E3 levels in 120,071 gravidas having California Expanded Alpha-Feto-protein prenatal screening at 15–20 weeks' gestation during a 5-year period. RESULTS Of the 120,071 women, 323 (0.27%) had low unconjugated E3 levels (less than or equal to 0.2 ng/mL, or 0.15 multiples of the median). Excluding women who were screened too early or who had indeterminate screening results, 103 (0.08%) women with unexplained low unconjugated E3 level remained; of these 103 women, 33 had negative screening results and 68 had positive screening results, and two were tested too late for interpretation. Intrauterine fetal death occurred in 39 (57%) of the 68 women with low unconjugated E3 and positive screening results and occurred in two (6%) of the 33 women with low unconjugated E3 levels and negative screening results, a significant difference (P < .001). Two cases of Smith–Lemli–Opitz syndrome were identified and the patients did not survive the neonatal period; one was a therapeutic abortion for severe oligohydramnios, and the other died at age 48 hours. Low unconjugated E3 level also predicted presence of steroid sulfatase deficiency, a much more common X-linked skin disorder characterized by ichthyosis. CONCLUSION Low maternal serum unconjugated E3 diagnosed more cases of steroid sulfatase deficiency and undetected intrauterine fetal death than Smith–Lemli–Opitz syndrome (1:60,000 prevalence), although the clinical importance of having this information prenatally is uncertain.
- 1 October 2002
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 110 (4) , 781-786
Cost-Benefit Analysis of Universal Tandem Mass Spectrometry for Newborn Screening
Objective. To estimate potential costs and benefits of routinely using tandem mass spectrometry (MS/MS) to screen newborns for inborn errors of metabolism. Method. Analysis of costs and benefits resulting from use of MS/MS in screening of 32 000 newborn infants using data from the Kaiser Permanente Medical Care Program of Northern California plus other published data. Setting. A large health maintenance organization. Results. In the base scenario, the cost per quality-adjusted life year saved by MS/MS screening was $5827; in the least favorable scenario, this cost was $11 419, and in the most favorable scenario, $736. Conclusion. Costs per quality-adjusted life year saved by MS/MS screening for inborn errors of metabolism compare favorably with other mass screening programs, including those for breast and prostate cancer.
- 1 October 2002
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 110 (4) , 781-786
Cost-Benefit Analysis of Universal Tandem Mass Spectrometry for Newborn Screening
Objective. To estimate potential costs and benefits of routinely using tandem mass spectrometry (MS/MS) to screen newborns for inborn errors of metabolism. Method. Analysis of costs and benefits resulting from use of MS/MS in screening of 32 000 newborn infants using data from the Kaiser Permanente Medical Care Program of Northern California plus other published data. Setting. A large health maintenance organization. Results. In the base scenario, the cost per quality-adjusted life year saved by MS/MS screening was $5827; in the least favorable scenario, this cost was $11 419, and in the most favorable scenario, $736. Conclusion. Costs per quality-adjusted life year saved by MS/MS screening for inborn errors of metabolism compare favorably with other mass screening programs, including those for breast and prostate cancer.
- 1 January 2001
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 20 (1) , 79-81
UNSUCCESSFUL VOLUNTARY PRENATAL TESTING FOR HUMAN IMMUNODEFICIENCY VIRUS INFECTION
Within the Kaiser Permanente system of Northern California, testing for HIV during prenatal vis its was encouraged. During a 5-year period the percentage of women agreeing to HIV testing increased from 50% to 76%. Eighty-three HIV-positive pregnancies occurred in 63 women. Only 17 (20%) of the 83 pregnancies were identified by the voluntary testing program.
- 1 January 2001
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 20 (1) , 79-81
UNSUCCESSFUL VOLUNTARY PRENATAL TESTING FOR HUMAN IMMUNODEFICIENCY VIRUS INFECTION
Within the Kaiser Permanente system of Northern California, testing for HIV during prenatal vis its was encouraged. During a 5-year period the percentage of women agreeing to HIV testing increased from 50% to 76%. Eighty-three HIV-positive pregnancies occurred in 63 women. Only 17 (20%) of the 83 pregnancies were identified by the voluntary testing program.
- 1 April 1999
- Published by Springer Nature in Pediatric Research
- Vol. 45 (4, Part 2 ) , 273A
Pitfalls of Voluntary Prenatal Human Immunodeficiency Virus (HIV) Screening
- 1 April 1999
- Published by Springer Nature in Pediatric Research
- Vol. 45 (4, Part 2 ) , 273A
Pitfalls of Voluntary Prenatal Human Immunodeficiency Virus (HIV) Screening